The study, funded by the Indian Council of Medical Research in New Delhi and conducted between September 2021 and May 2023, focused on potential post-COVID-19 vaccination syndrome (PCVS) and its impact on the quality of life (QoL) among Indian adults aged 18 and above who received either Bharat Biotech's COVAXIN or the AstraZeneca COVID-19 vaccines. (Related: Australian actress sues AstraZeneca for life-threatening vaccine injury, but continues to ADVOCATE for other COVID-19 "vaccines.")
According to study authors Yogendra Shrestha and Rajesh Venkataraman from the Department of Pharmacy Practice, Sri Adichunchanagiri College of Pharmacy, 52.8 percent of the vaccine recipients experienced at least one PCVS a month after their first vaccination. Shockingly, this number increased to 64.6 percent at the 12-month mark. Overall, the PCVS was higher among vaccinated individuals with AstraZeneca (65.59 percent) compared to COVAXIN (59.4 percent).
Notably, individuals who opted for booster shots revealed even higher rates of PCVS, with over 80 percent reporting complications. This contrasts sharply with the unvaccinated group, where only 50 percent reported a similar syndrome. In other words, the occurrence of PCVS decreases over time but increases after booster shots. The QoL improves over time but declines after boosters.
Furthermore, the authors noted that discussions about the impact of immunization on people with long-term COVID have led to varying opinions.
“Some evidence indicates a change in, an improvement in, a continuation of, or even a worsening of long-term COVID-19 symptoms following vaccination. The ratio of change in antibody titers was noticeably larger in the group of people whose illnesses became worse.”
CDC still recommends COVID-19 vaccines despite evidence of adverse effects from several studies
This controversial study adds to a growing body of research suggesting potential health complications associated with COVID-19 vaccinations.
A March review, published in the National Library of Medicine, analyzed 81 articles confirming cardiovascular complications in 17,636 individuals who had received an mRNA vaccine. The study reported 284 deaths, with thrombosis being a frequent concern associated with mRNA shots.
Pfizer's vaccine was linked to thrombosis, while Moderna's vaccine recipients experienced a higher incidence of stroke. Cardiologist Peter McCullough described the findings as a "cardiovascular safety disaster," questioning public health agencies for the continuous promotion of these vaccines.
In a Substack post on Nov. 11, McCullough emphasized that 284 well-described deaths due to cardiovascular and thrombotic complications should prompt a global recall of the vaccines. The time between vaccination and the onset of symptoms was reported to be 5.6 days for Moderna and 4.8 days for Pfizer.
Moreover, a preprint study published on medRxiv revealed common chronic symptoms among vaccine recipients, including excessive fatigue, brain fog, numbness, neuropathy and exercise intolerance. At least half of the participants, with a median of 22 symptoms, also reported dizziness, burning sensations, tinnitus, headache, insomnia, palpitations and myalgia.
But despite all these concerns, the Centers for Disease Control and Prevention still recommends the 2023-2024 updated COVID-19 vaccines from Pfizer, Moderna and Novavax, even for children as young as six months old. The agency insists that these vaccinations are necessary to protect against serious illness from COVID-19. However, recent government files revealed that over five million COVID-19 infections in 2021 occurred among vaccinated individuals.
Learn more about the dangers of COVID-19 vaccines at Vaccines.news.
Watch U.K. Member of Parliament Andrew Bridgen calling for the suspension of mRNA COVID-19 vaccines in the House of Commons.
This video is from the channel The Big Logic channel on Brighteon.com.
More related stories:
Sources include:
Please contact us for more information.
